SCHEMBL5544260

SCHEMBL5544260

O=COCc1ccccc1-c1csnn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.47
KMT2A Q03164 7/20 0.40
ALDH1A1 P00352 2/20 0.40
RAB9A P51151 3/20 0.40
POLB P06746 3/20 0.40
MEN1 O00255 2/20 0.40
NPC1 O15118 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
CYP2C19 P33261 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
MAPT P10636 2/20 0.35
MGLL Q99685 1/20 0.34
PKM P14618 1/20 0.33
NOTUM Q6P988 1/20 0.33
GAA P10253 2/20 0.32
AKT1 P31749 1/20 0.31
PTPN1 P18031 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5544256 0.79 LMNA (0.47) LMNAKMT2AALDH1A1RAB9APOLB
SCHEMBL507525 0.74 LMNA (0.56) LMNAKMT2AALDH1A1RAB9APOLB
SCHEMBL5855543 0.74 LMNA (0.61) LMNAKMT2AALDH1A1RAB9APOLB
SCHEMBL508109 0.74 LMNA (0.56) LMNAKMT2AALDH1A1RAB9APOLB
SCHEMBL27813515 0.74 KMT2A (0.52) LMNAKMT2AALDH1A1RAB9APOLB
SCHEMBL5540568 0.73 KMT2A (0.55) LMNAKMT2AALDH1A1RAB9APOLB
SCHEMBL5541978 0.71 KMT2A (0.47) KMT2AALDH1A1RAB9APOLBMEN1
SCHEMBL11406620 0.71 SRC (0.40) LMNAKMT2AALDH1A1RAB9AMEN1
SCHEMBL5544710 0.71 DPP4 (0.48) KMT2A
SCHEMBL19449576 0.69 BRD4 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 LMNA 4152/4885KMT2A 4267/4885ALDH1A1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.